Nothing Special   »   [go: up one dir, main page]
Skip to main content
Springer Nature Link
Log in

Oxidant stress—a major cause of reduced endothelial nitric oxide availability in cardiovascular disease

  • Review Article
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Common conditions predisposing to atherosclerosis, such as dyslipidemia, hypertension, diabetes, and smoking, are associated with increased vascular production of reactive oxygen species (ROS). One of the major consequences of increased vascular ROS production is a reduction of endothelial nitric oxide (NO) bioavailability. Importantly, endothelial NO not only produces endothelium-dependent vasodilation but also has potent antiatherogenic properties, including inhibition of platelet aggregation and adhesion molecule expression. This concept has been supported by several recent clinical studies, suggesting a close association of impaired endothelium-dependent vasomotion and clinical cardiovascular events. Increased vascular ROS production reduces endothelial NO not only by direct inactivation, but also as a consequence of increased oxidation of tetrahydrobiopterin and inhibition of dimethylarginine dimethylaminohydrolase. This may in part explain the profound impact of increased endothelial oxidant stress on endothelial NO bioactivity. An increased activity of NAD(P)H oxidase, a major vascular oxidant enzyme system, has been observed in both experimental atherosclerosis and human coronary disease and likely represents an important source of ROS. Moreover, NAD(P)H oxidase has been shown to cause endothelial NO synthase “uncoupling” and to promote xanthine oxidase-dependent superoxide production. In addition, in human coronary disease a reduced vascular activity of the antioxidant enzyme extracellular superoxide dismutase has been observed. Notably, cardiovascular treatment strategies such as statin, angiotensin-converting enzyme (ACE) inhibitor, and angiotensin I receptor blocker treatment may exert potent “antioxidant” effects by reducing NAD(P)H oxidase and increasing extracellular superoxide dismutase activity, leading to improved endothelial function. Restoring endothelial function has become an attractive therapeutic target, given accumulating observations supporting a prognostic role of endothelial dysfunction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340:115–126

    Article  PubMed  CAS  Google Scholar 

  2. Vita JA, Keaney JF Jr (2002) Endothelial function: a barometer for cardiovascular risk? Circulation 106:640–642

    Article  PubMed  Google Scholar 

  3. Landmesser U, Harrison DG (2001) Oxidant stress as a marker for cardiovascular events: Ox marks the spot. Circulation 104:2638–2640

    PubMed  CAS  Google Scholar 

  4. Tsao PS, McEvoy LM, Drexler H, Butcher EC, Cooke JP (1994) Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation 89:2176–2182

    PubMed  CAS  Google Scholar 

  5. Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R (1995) Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res 76:980–986

    PubMed  CAS  Google Scholar 

  6. Tomita H, Egashira K, Kubo-Inoue M, Usui M, Koyanagi M, Shimokawa H, Takeya M, Yoshimura T, Takeshita A (1998) Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arterioscler Thromb Vasc Biol 18:1456–1464

    PubMed  CAS  Google Scholar 

  7. Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, Picard MH, Huang PL (2001) Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 104:448–454

    Article  PubMed  CAS  Google Scholar 

  8. Schachinger V, Britten MB, Zeiher AM (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101:1899–1906

    PubMed  CAS  Google Scholar 

  9. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A (2000) Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101:948–954

    PubMed  CAS  Google Scholar 

  10. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T (2001) Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104:2673–2678

    Article  PubMed  CAS  Google Scholar 

  11. Halcox JPJ, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KRA, Quyyumi AA (2002) Prognostic value of coronary vascular endothelial dysfunction. Circulation 106:653–658

    Article  PubMed  Google Scholar 

  12. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97:1916–1923

    Article  PubMed  CAS  Google Scholar 

  13. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG (1997) Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 95:588–593

    PubMed  CAS  Google Scholar 

  14. Mugge A, Elwell JH, Peterson TE, Hofmeyer TG, Heistad DD, Harrison DG (1991) Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits. Circ Res 69:1293–1300

    PubMed  CAS  Google Scholar 

  15. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, Tarpey M, Fukai T, Harrison DG (2001) Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 103:1282–1288

    PubMed  CAS  Google Scholar 

  16. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF Jr, Vita JA (1996) Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 93:1107–1113

    PubMed  CAS  Google Scholar 

  17. Hornig B, Arakawa N, Kohler C, Drexler H (1998) Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 97:363–368

    PubMed  CAS  Google Scholar 

  18. Landmesser U, Merten R, Spiekermann S, Buttner K, Drexler H, Hornig B (2000) Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 101:2264–2270

    PubMed  CAS  Google Scholar 

  19. Andrews NP, Prasad A, Quyyumi AA (2001) N-acetylcysteine improves coronary and peripheral vascular function. J Am Coll Cardiol 37:117–123

    Article  PubMed  CAS  Google Scholar 

  20. Prasad A, Andrews NP, Padder FA, Husain M, Quyyumi AA (1999) Glutathione reverses endothelial dysfunction and improves nitric oxide bioavailability. J Am Coll Cardiol 34:507–514

    Article  PubMed  CAS  Google Scholar 

  21. Landmesser U, Drexler H (2002) Toward understanding of extracellular superoxide dismutase regulation in atherosclerosis: a novel role of uric acid? Arterioscler Thromb Vasc Biol 22:1367–1368

    Article  PubMed  CAS  Google Scholar 

  22. Mugge A, Elwell JH, Peterson TE, Harrison DG (1991) Release of intact endothelium-derived relaxing factor depends on endothelial superoxide dismutase activity. Am J Physiol 260:C219–C225

    PubMed  CAS  Google Scholar 

  23. Omar HA, Cherry PD, Mortelliti MP, Burke-Wolin T, Wolin MS (1991) Inhibition of coronary artery superoxide dismutase attenuates endothelium-dependent and -independent nitrovasodilator relaxation. Circ Res 69:601–608

    PubMed  CAS  Google Scholar 

  24. Lynch SM, Frei B, Morrow JD, Roberts LJ II, Xu A, Jackson T, Reyna R, Klevay LM, Vita JA, Keaney JF Jr (1997) Vascular superoxide dismutase deficiency impairs endothelial vasodilator function through direct inactivation of nitric oxide and increased lipid peroxidation. Arterioscler Thromb Vasc Biol 17:2975–2981

    PubMed  CAS  Google Scholar 

  25. Stralin P, Karlsson K, Johansson BO, Marklund SL (1995) The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. Arterioscler Thromb Vasc Biol 15:2032–2036

    PubMed  CAS  Google Scholar 

  26. Fukai T, Folz RJ, Landmesser U, Harrison DG (2002) Extracellular superoxide dismutase and cardiovascular disease. Cardiovasc Res 55:239–249

    Article  PubMed  CAS  Google Scholar 

  27. Jung O, Marklund SL, Geiger H, Pedrazzini T, Busse R, Brandes RP (2003) Extracellular superoxide dismutase is a major determinant of nitric oxide bioavailability: in vivo and ex vivo evidence from ecSOD-deficient mice. Circ Res 93:622–629

    Article  PubMed  CAS  Google Scholar 

  28. Karlsson K, Marklund SL (1987) Heparin-induced release of extracellular superoxide dismutase to human blood plasma. Biochem J 242:55–59

    PubMed  CAS  Google Scholar 

  29. Juul K, Tybjaerg-Hansen A, Marklund S, Heegaard NH, Steffensen R, Sillesen H, Jensen G, Nordestgaard BG (2004) Genetically reduced antioxidative protection and increased ischemic heart disease risk: the Copenhagen City Heart Study. Circulation 109:59–65

    Article  PubMed  CAS  Google Scholar 

  30. Cai H, Harrison DG (2000) Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87:840–844

    PubMed  CAS  Google Scholar 

  31. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, Bohm M, Meinertz T, Munzel T (1999) Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 99:2027–2033

    PubMed  CAS  Google Scholar 

  32. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK (1996) p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 271:23317–23321

    Article  PubMed  CAS  Google Scholar 

  33. Lavigne MC, Malech HL, Holland SM, Leto TL (2001) Genetic demonstration of p47phox-dependent superoxide anion production in murine vascular smooth muscle cells. Circulation 104:79–84

    Article  PubMed  CAS  Google Scholar 

  34. Li JM, Shah AM (2003) Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. J Biol Chem 278:12094–12100

    Article  PubMed  CAS  Google Scholar 

  35. Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, Jo H, Holland SM, Harrison DG (2002) Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 40:511–515

    Article  PubMed  CAS  Google Scholar 

  36. Brandes RP, Miller FJ, Beer S, Haendeler J, Hoffmann J, Ha T, Holland SM, Gorlach A, Busse R (2002) The vascular NADPH oxidase subunit p47phox is involved in redox-mediated gene expression. Free Radic Biol Med 32:1116–1122

    Article  PubMed  CAS  Google Scholar 

  37. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG (2003) Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial nitric oxide synthase in hypertension: role of the NAD(P)H oxidase. J Clin Invest 111:1201–1209

    PubMed  CAS  Google Scholar 

  38. Li JM, Wheatcroft S, Fan LM, Kearney MT, Shah AM (2004) Opposing roles of p47phox in basal versus angiotensin II-stimulated alterations in vascular O2- production, vascular tone, and mitogen-activated protein kinase activation. Circulation 109:1307–1313

    Article  PubMed  CAS  Google Scholar 

  39. Azumi H, Inoue N, Takeshita S, Rikitake Y, Kawashima S, Hayashi Y, Itoh H, Yokoyama M (1999) Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation 100:1494–1498

    PubMed  CAS  Google Scholar 

  40. Spiekermann S, Landmesser U, Dikalov S, Gamez G, Tatge H, Hornig B, Drexler H, Harrison DG (2003) Electron spin resonance characterization of vascular NAD(P)H- and xanthine-oxidase-activity in patients with coronary artery disease: relation to endothelium dependent vasodilation. Circulation 107:1383–1389

    Article  PubMed  CAS  Google Scholar 

  41. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, Tordo P, Pritchard KA Jr (1998) Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A 95:9220–9225

    Article  PubMed  CAS  Google Scholar 

  42. Alp NJ, Channon KM (2004) Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 24:413–420

    Article  PubMed  CAS  Google Scholar 

  43. Barry-Lane PA, Patterson C, van der Merwe M, Hu Z, Holland SM, Yeh ET, Runge MS (2001) p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J Clin Invest 108:1513–1522

    PubMed  CAS  Google Scholar 

  44. Tiefenbacher CP, Bleeke T, Vahl C, Amann K, Vogt A, Kubler W (2000) Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis. Circulation 102:2172–2179

    PubMed  CAS  Google Scholar 

  45. Ozaki M, Kawashima S, Yamashita T, Hirase T, Namiki M, Inoue N, Hirata K, Yasui H, Sakurai H, Yoshida Y, Masada M, Yokoyama M (2002) Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest 110:331–340

    PubMed  CAS  Google Scholar 

  46. Houston M, Estevez A, Chumley P, Aslan M, Marklund S, Parks DA, Freeman BA (1999) Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J Biol Chem 274:4985–4994

    Article  PubMed  CAS  Google Scholar 

  47. Adachi T, Fukushima T, Usami Y, Hirano K (1993) Binding of human xanthine oxidase to sulphated glycosaminoglycans on the endothelial-cell surface. Biochem J 289:523–527

    PubMed  CAS  Google Scholar 

  48. Ohara Y, Peterson TE, Harrison DG (1993) Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 91:2546–2551

    Article  PubMed  CAS  Google Scholar 

  49. White CR, Darley-Usmar V, Berrington WR, McAdams M, Gore JZ, Thompson JA, Parks DA, Tarpey MM, Freeman BA (1996) Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci U S A 93:8745–8749

    Article  PubMed  CAS  Google Scholar 

  50. McNally JS, Davis ME, Giddens DP, Saha A, Hwang J, Dikalov S, Jo H, Harrison DG (2003) Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. Am J Physiol Heart Circ Physiol 285:H2290–H2297

    PubMed  CAS  Google Scholar 

  51. Cooke JP (2000) Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 20:2032–2037

    PubMed  CAS  Google Scholar 

  52. Kinlay S, Behrendt D, Fang JC, Delagrange D, Morrow J, Witztum JL, Rifai N, Selwyn AP, Creager MA, Ganz P (2004) Long-term effect of combined vitamins E and C on coronary and peripheral endothelial function. J Am Coll Cardiol 43:629–634

    Article  PubMed  CAS  Google Scholar 

  53. Hornig B, Landmesser U, Kohler C, Ahlersmann D, Spiekermann S, Christoph A, Tatge H, Drexler H (2001) Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 103:799–805

    PubMed  CAS  Google Scholar 

  54. Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, Sauer H, Bohm M, Nickenig G (2001) Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 59:646–654

    PubMed  CAS  Google Scholar 

  55. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M (2000) Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 20:61–69

    PubMed  CAS  Google Scholar 

  56. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, Manes C, Fischer D, de Groot K, Fliser D, Fauler G, Marz W, Drexler H (2005) Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111:2356–2363

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung Kardiologie und Angiologie, Medizinische Hochschule Hannover, Carl Neuberg Str. 1, 30625, Hannover, Germany

    Ulf Landmesser & Helmut Drexler

  2. Division of Cardiology, Emory University School of Medicine and Atlanta Veterans Administration Hospital, Atlanta, GA, USA

    David G. Harrison

Authors
  1. Ulf Landmesser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David G. Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Helmut Drexler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulf Landmesser.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Landmesser, U., Harrison, D.G. & Drexler, H. Oxidant stress—a major cause of reduced endothelial nitric oxide availability in cardiovascular disease. Eur J Clin Pharmacol 62 (Suppl 1), 13–19 (2006). https://doi.org/10.1007/s00228-005-0012-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-005-0012-z

Keywords

Search

Navigation